Wells Fargo analyst Tiago Fauth raised the firm’s price target on PTC Therapeutics (PTCT) to $93 from $73 and keeps an Overweight rating on the shares. The firm notes the PKU launch is off to a strong start, and without stocking this represents organic uptake. Wells thinks persistence, and degree of switching will be key. FDA meeting on votoplam could be a sleepy catalyst, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $68 from $46 at Barclays
- PTC Therapeutics price target raised to $75 from $50 at Citi
- PTC Therapeutics: Strong Market Position and Growth Potential Drive Buy Rating
- PTC Therapeutics: Balancing Sephience Success with DMD Challenges and Strategic Shifts
- PTC Therapeutics Reports Strong Q3 2025 Results